CHMFL-48

• Description :

  CHMFL-48 is an orally active BCR-ABL kinase inhibitor targeting both wild-type (wt) and various imatinib-resistant mutants. The IC50 values for CHMFL-48 against ABL wild-type and ABL T315I mutant are 1 nM and 0.8 nM, respectively. CHMFL-48 exerts its effects by blocking the autophosphorylation of BCR-ABL wild-type and mutant forms, which impacts downstream signaling mediators such as STAT5 and CRKL, leading to cell cycle arrest and induction of apoptosis. CHMFL-48 holds potential for research into chronic myeloid leukemia (CML) [1].

• UNSPSC :

  12352005

• Target :

  Apoptosis; Bcr-Abl; STAT

• Type :

  Reference compound

• Related Pathways :

  Apoptosis; JAK/STAT Signaling; Protein Tyrosine Kinase/RTK; Stem Cell/Wnt

• Field of Research :

  Cancer

• Assay Protocol :

  https://www.medchemexpress.com/chmfl-48.html

• Smiles :

  CC1=C(N2C=C(C3=CN=C(NC=C4)C4=C3)C=N2)C=C(NC(C5=CC=C(CN6CCN(C)CC6)C(C(F)(F)F)=C5)=O)C=C1

• Molecular Formula :

  C31H30F3N7O

• Molecular Weight :

  573.61

• References & Citations :

  [1]Lu T, et al. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML) . Eur J Pharmacol. 2021 Apr 15;897:173944.

• Shipping Conditions :

  Room temperature

• Scientific Category :

  Reference compound1

• Clinical Information :

  No Development Reported

• Isoform :

  Bcr-Abl; STAT5

• CAS Number :

  [2479290-65-6]